Exploring Immunotherapy in Non-Small Cell Lung Cancer: A Review
DOI:
https://doi.org/10.58445/rars.1121Keywords:
Immunotherapy, Non-Small Cell Lung Cancer, treatmentAbstract
In this review paper, we will go deeper into the use of immunotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC), the big cause of death in those suffering from cancer globally. Immunotherapy is one of the most innovative cancer treatments which enables the body's natural defenses to face and destroy cancerous cells. This interprets an emerging pattern for cancer treatment that surpasses traditional treatment methods. In NSCLC, patients have been helped by these drugs like pembrolizumab and nivolumab in increasing survival rates. On the other hand, the variability of the treatment response and the possible side effects are the issues that still need to be worked on. The continuous work, such as the clinical trials that test the influences of gene mutations on treatment effectiveness, is focused on solving these problems. Personalized medicine as well as individual approaches for immunotherapy are directed to maximize the success of the treatment of people with NSCLC. However, the risks involved in immunotherapy cannot be overlooked and this approach presents a revolutionary potential in the treatment of NSCLC, providing more personalized and effective cancer care.
References
Addeo, A., Banna, G. L., & Friedlaender, A. (2021, May 21). Kras G12C mutations in NSCLC: From target to resistance. MDPI. https://www.mdpi.com/2072-6694/13/11/2541
EGFR and lung cancer. American Lung Association. (2022, November 17). https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr#:~:text=EGFR%2Dpositive%20lung%20cancer%20represents,minimal%20to%20no%20smoking%20history.
Elflein, J. (2022, November 24). Global consumption of cigarettes 1880-2020. Statista. https://www.statista.com/statistics/279577/global-consumption-of-cigarettes-since-1880/
Elflein, J. (2023, August 29). Major cancer types by deaths worldwide 2020. Statista. https://www.statista.com/statistics/288580/number-of-cancer-deaths-worldwide-by-type/#:~:text=Lung%20cancer%20is%20the%20deadliest,1.79%20million%20deaths%20in%202020.
Gu, Y., Zhang, J., Zhou, Z., Liu, D., Zhu, H., Wen, J., Xu, Z., Chen, T., & Fan, M. (2020, February 1). Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study. NCBI. Retrieved February 26, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961775/
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., Hayman, J., Heist, R. S., Horn, L., Jahan, T., Koczywas, M., Jr, B. W. L., Merritt, R. E., Moran, C. A., Niell, H. B., … Hughes, M. (2013, January 1). Small cell lung cancer. JNCCN. https://jnccn.org/view/journals/jnccn/11/1/article-p78.xml
Lim, S. M., Hong, M. H., & Kim, H. R. (2020). Immunotherapy for non-small cell lung cancer: current landscape and future perspectives. Immune Network, 20(1).
Malhotra, J., Jabbour, S. K., & Aisner, J. (2017). Current state of immunotherapy for non-small cell lung cancer. Translational lung cancer research, 6(2), 196.
Massafra, M., Passalacqua, M. I., Gebbia, V., Macrì, P., Lazzari, C., Gregorc, V., Buda, C., Altavilla, G., & Santarpia, M. (2021). Immunotherapeutic advances for NSCLC. Biologics: Targets and Therapy, Volume 15, 399–417. https://doi.org/10.2147/btt.s295406
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008, May). Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718421/
Pyo, K. H., Kim, J. H., Lee, J. M., Kim, S. E., Cho, J. S., Lim, S. M., & Cho, B. C. (2019). Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Lung Cancer, 127, 112-121.
Subramanian, J., Morgensztern, D., Goodgame, B., Baggstrom, M. Q., Gao, F., Piccirillo, J., & Govindan, R. (n.d.). Distinctive characteristics of non-small cell lung cancer (NSCLC) ... Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis. https://www.sciencedirect.com/science/article/pii/S1556086415329622
Yale Medicine. (2022, October 26). Non-small cell lung cancer. Yale Medicine. https://www.yalemedicine.org/conditions/non-small-cell-lung-cancer#:~:text=What%20is%20non%2Dsmall%20cell,rapidly%20and%20out%20of%20control.
Zhou, L., Wang, X. L., Deng, Q. L., Du, Y. Q., & Zhao, N. Q. (2016). The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Scientific Reports, 6(1), 32020.
NCT04405661
NCT04909684
Downloads
Posted
Categories
License
Copyright (c) 2024 Kavan Shah
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.